ArticleLeukemia2020
An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.Blood advances · 2023Trial
- Article
- Review
- Advancing drug development in myelodysplastic syndromes.Blood advances · 2025Review
- Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancy.Journal of geriatric oncology · 2025Article
- Review
- Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.Blood advances · 2023Article
- Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes.JCO oncology practice · 2023Article
- Article
- [Application of patient-reported-outcome in myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Advances in Management for Older Adults With Hematologic Malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Review
- Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.Cancers · 2021Review
- Diagnosis of frailty in geriatric patients: Is the pictorial fit frail scale an appropriate screening tool in hospital settings?Caspian journal of internal medicine · 2021Article
- Frailty in inflammatory bowel diseases: an emerging concept.Therapeutic advances in gastroenterology · 2021Review
- Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.Hematology. American Society of Hematology. Education Program · 2020Article
- Article
- Integrating patient-centered factors in the risk assessment of MDS.Hematology. American Society of Hematology. Education Program · 2019Review
- Air Pollutants and Frailty in Older Adults: A Geriatrician's Perspective.Annals of geriatric medicine and research · 2019Article
- Geriatric assessment for the practicing clinician: The why, what, and how.CA: a cancer journal for cliniciansReview
Corrections and comments
- Commented on by
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frailty index (FI) is based on the principle that the more deficits an individual has, the greater their risk of adverse outcomes. It is expressed as a ratio of the number of deficits present to the total number of deficits considered. We developed an MDS-specific FI using a prospective MDS registry and assessed its ability to add prognostic power to conventional prognostic scores in MDS. The 42 deficits included in this FI included measurements of physical performance, comorbidities, laboratory values, instrumental activities of daily living, quality of life and performance status. Of 644 patients, 440 were eligible for FI calculation. The median FI score was 0.25 (range 0.05-0.67), correlated with age and IPSS/IPSS-R risk scores and discriminated overall survival. With a follow-up of 20 months, survival was 27 months (95% CI 24-30.4). By multivariate analysis, age >70, FI, transfusion dependence, and IPSS were significant covariates associated with OS. The incremental discrimination improvement of the frailty index was 37%. We derived a prognostic score with five risk groups and distinct survivals ranging from 7.4 months to not yet reached. If externally validated, the MDS-FI could be used as a tool to refine the risk stratification of current clinical prognostication models.
Indexed as
Identifiers
31811236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.